Chris Abraham, PhD, is the Director of Application Development at Kytopen, where he leads the development of novel applications and platform optimization for Flowfect® technology. He leads a specialized team of field application scientists, driving strategic collaborations with external partners to accelerate the discovery and manufacturing of gene-modified cell therapies.

With over a decade of experience, Chris has dedicated his career to advancing non-viral gene delivery through expert workflow and assay development. His extensive expertise in RNP-based workflowsand high-throughput screening was honed through leadership roles at pioneering biotechnology firms, including Inscripta, Inc and Artisan Bio.

Chris earned his PhD in Microbiology from the University of Colorado Anschutz Medical Campus and completed postdoctoral research funded by the American Cancer Society at the University of Colorado Boulder, focusing on CRISPR-based functional genomics in cancer models.

Chris will be a scientific lead for the transfection workflows and processing.